Translator: 文珮(manpui)#3013 by Canada Vancouver Sailing Farm

Picture from :

 This article is excerpted from clinical research paper titled “COMBINATION THERAPY FOR COVID-19 BASED ON IVERMECTIN IN AN AUSTRALIAN POPULATION”  published in trialsitenews on October 19, 2021 by Thomas J. Borody et al., Centre for Digestive Diseases, Five Dock, NSW, Australia and Faculty of Health and Medicine, University of Newcastle, NSW, Australia.  This paper mainly introduces the clinical research conclusions of ivermectin triple therapy (ITT) of ivermectin, doxycycline and zinc in reducing the risk of hospitalization and death in patients with COVID-19.

 Between June 1, 2021 and September 30, 2021, 10-day Ivermectin Triple Therapy (ITT) was administered to 600 outpatients who were positive for COVID-19 by PCR test within two days.  

 The specific medication method is: ivermectin 24 mg/day, doxycycline 100mg/day and zinc 50 mg/day to be taken 30 minutes before dinner every day.

 Seven percent of patients also used vitamins and nutritional supplements.

 Only 7% had mild adverse reactions to treatment, mainly mild gut symptoms such as nausea, diarrhea, and heartburn.  But no one stopped the dosage regimen because of this.

 In the end, only 5 people (0.83%) required hospitalization and no one died.

 Of the 600 patients in the control group, 70 (11.7%) required hospitalization and 6 died (1%).

 Ivermectin triple therapy (ITT) with ivermectin, doxycycline, and zinc was shown to reduce the risk of death by 92.3% and hospitalization by 92.9%.

 Researchers classified patients with early diagnosis of COVID-19 according to fever, headache, cough, loss of taste, loss of smell, diarrhea, vomiting, fatigue, muscle pain and joint pain. The severity of these 10 common COVID-19 symptoms is divided into different scores ranging from 0 to 10 according to the monitoring value of the visual analogue scale.  0 means no related symptoms, 10 is the most severe symptom.  The total symptom severity score is the sum of the 10 symptom scores for a total of 100 points.  The oxygen saturation reading scored was 100%.

 Of these, 126 hotel or home quarantined patients with an average age of 42 years (17-94 years) in the test group were available for detailed assessment of symptoms and oxygenation status.

 Monitoring of the Covid-19 infection symptom visual analogue  scale for these 126 patients showed that after 10 days of ivermectin triple therapy, the patients had a median total symptom severity score of 37 from the start of treatment (range: 0  ~100) down to 3 points at the end of treatment (range: 0~62).

 The study showed that although loss of smell/taste, cough, and fatigue persisted for longer, all symptom severity scores decreased significantly after the 10-day treatment period.  Symptom relief in Covid-19 patients without ivermectin triple therapy usually takes 2 to 4 weeks.

 The use of ivermectin triple therapy was demonstrated to have significant efficacy in patients with COVID-19.

 The final result is as follows:

 N in the table represents the number of patients with this symptom

 SD means standard deviation

 *A nonparametric paired t-test was performed


Aothur: Macheal Tonny by Canada Vancouver Sailing Farm